Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma

More documents

Recommendations

Info

Chapter 4 A single QST parameter as a tool for mechanism-based investigation of neuropathic pain Konopka K.H., Harbers M., Houghton A., Kortekaas R., van Vliet A., Timmerman W., den Boer J.A., Struys M.M.R.F., van Wijhe M. submitted
4. QST and neuropathic pain mechanisms Abstract Quantitative sensory testing (QST) allows the somatosensory profiling of patients with neuropathic pain. The ultimate goal of identifying differences in the responsiveness to sensory stimuli is the identification of differences in the mechanisms responsible for generating sensory abnormalities and their subsequent mechanism-based therapy. Recently, it was shown that distinct somatosensory patterns using a battery of QST tests are present in the different clinical entities of neuropathic pain. Until now, it has not been investigated whether the responsiveness to a single QST parameter would reveal different patient subgroups. Thus, we studied patients with neuropathic pain for their responsiveness to a single QST parameter “Mechanical Pain Sensitivity” (MPS). Abnormal MPS score reflects hypersensitivity for mechanical stimulation, which occurs in ~30% of the neuropathic pain patient population. The MPS test obtains stimulus-response function to seven pinprick devices exerting forces between 8-512mN to identify abnormalities for pinprick pain. In this study we found that patients with MPS abnormalities showed two distinctive patterns of altered stimulus-response function to pinpricks. 40% of patients reported a stimulus dependent pain response whereas 60% of patients did not show such stimulus dependent behaviour and rated all pinprick intensities equally painful. Both types of responses were found within different clinical entities of neuropathic pain. Hence, we show that even a single QST parameter can reveal additional, more detailed information of sensory abnormalities in neuropathic pain. Further evaluation might lead to the identification of differences in the mechanisms responsible for these distinct MPS abnormalities.
Page 2:
Quantitative Sensory Testing (QST)
Page 5 and 6:
Promotores: Prof. dr. M.M.R.F. Stru
Page 7 and 8:
Paranimfen Marten Harbers Aribert B
Page 9 and 10:
Contents 3.3.4. Sensory changes at
Page 11:
0 Contents Chapter 5 Do patients wi
Page 14:
Chapter 1 General introduction
Page 17 and 18: 1. General introduction stimuli. C-
Page 19 and 20: 1. General introduction Patients re
Page 21 and 22: 1. General introduction 0 drugs (NS
Page 23 and 24: 1. General introduction Table 1-2:
Page 26 and 27: Chapter 2 Bilateral sensory abnorma
Page 28 and 29: 2. Bilateral abnormalities in neuro
Page 46: 2. Bilateral abnormalities in neuro
Page 49 and 50: 3. Somatosensory function and neuro
Page 51 and 52: 0 3. Somatosensory function and neu
Page 65: 3. Somatosensory function and neuro
Page 69 and 70: 4. QST and neuropathic pain mechani
Page 81 and 82: 5. QST in patients with tendinopath
Page 94 and 95: Chapter 6 General discussion and Su
Page 96 and 97: 6. General discussion and Summary s
Page 98 and 99: 6. General discussion and Summary s
Page 100 and 101: 6. General discussion and Summary T
Page 102 and 103: 6. General discussion and Summary Q
Page 104 and 105: 6. General discussion and Summary S
Page 106 and 107: References Abate M, Silbernagel KG,
Page 108 and 109: de la Llave-Rincon AI, Fernandez-de
Page 110 and 111: Kehlet H, Jensen TS, Woolf CJ. 2006
Page 112 and 113: Robinson JM, Cook JL, Purdam C, Vis
Page 114 and 115: Visentini PJ, Khan KM, Cook JL, Kis
Page 116 and 117:
Nederlandse samenvatting Met de ont
Page 118 and 119:
Acknowledgement To produce a work s
show all

Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma

Create successful ePaper yourself

Delete template?

Save as template?